With the exception of empirical information, the matters discussed in this website are forward-looking statements that involve a number of risks and uncertainties. The actual future consequences for TrioxBio could differ significantly from these statements.
Factors that could cause such a discrepancy between forward-looking statement and actual fact include risks and uncertainties such as: the inability to finance the company's operations, the inability to hire and retain qualified personnel, and/or changes in the general economic climate. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," the negative of such terms, and other comparable terminology.
Our statements are only predictions. Although we believe that the expectations reflected in this website are reasonable, such statements should not be regarded as a representation by TrioxBio, or any other person, that such forward-looking predictions will ultimately be achieved. We do not assume responsibility to update any of the forward-looking statements included here, whether as a result of new information, future events or otherwise. In light of the above, readers are cautioned not to place undue reliance on such forward-looking statements.
This release does not constitute an offer to sell, or a solicitation of offers to buy, any securities of any entity.
News & Media
August 29, 2016:
"The FDA's Office of Orphan Products Development granted TrioxBio Inc. its orphan-drug designation request of S-ethylisothiouronium diethylphosphate (MTR-107) for treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH) including symptomatic hypotension in the immediate post-dialytic period."
January 17, 2016:
" TrioxBio Inc. submitted an Orphan-drug designation request to FDA authorities for the treatment of chronic or recurrent symptomatic intradialytic hypotension (IDH)."